PRODUCT LITERATURE

Clinical Pharmacology of Eptifibatide

---

Activation of receptor function of platelet membrane
glycoprotein (GP) IIb-IIIa leads to the binding of fibrinogen and is the final common pathway to platelet aggregation. Platelet aggregates provide the structural basis
for coronary thrombosis, a major cause of ischemic
heart disease. GP IIb-IIIa has a narrow tissue distribution, being found only on platelets and their progenitors,
and inhibition of its receptor function has emerged as a
promising new therapeutic strategy for management of
acute ischemic coronary syndromes and acute ischemic
complications of percutaneous coronary interventions.
Eptifibatide (INTEGRILIN) is a cyclic heptapeptide inhibitor of GP IIb-IIIa, with an active pharmacophore that is
derived from the structure of barbourin, a GP IIb-IIIa
inhibitor from the venom of the southeastern pigmy
rattlesnake. Like barbourin, eptifibatide is a specific and
robust inhibitor of the GP IIb-IIIa receptor function, having a low affinity for other integrins and strongly preventing platelet aggregation

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Ebatid

Specific Detail Info

Am J Cardiol 1997;80(4A):11B–20B

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment